Manage your formulary budget
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
|Title:||Inhibitors of thrombin|
|Abstract:||This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.|
|Inventor(s):||Maraganore; John M. (Concord, MA), Fenton, II; John W. (Malden Bridge, NY), Kline; Toni (New York, NY)|
|Assignee:||Biogen, Inc. (Cambridge, MA) Health Research, Inc. (Albany, NY)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition; Device;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.